Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jul 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a special treatment option for women with early-stage endometrial cancer, specifically those with Stage IA cancer that is not deeply invading the muscle layer of the uterus. The aim is to see if a fertility-sparing therapy can be safely offered to women who want to preserve their ability to have children, even while treating their cancer. The researchers want to compare two groups of women: those whose tumors have invaded the muscle layer of the uterus less than halfway and those whose tumors have not invaded it at all.

To be eligible for this trial, women need to be between 18 and 45 years old and have a specific type of endometrial cancer that is classified as G1 or G2, which relates to how aggressive the cancer is. They should also have a strong desire to preserve their fertility and be able to provide informed consent. If you join this study, you can expect careful monitoring and support from the research team as you undergo the trial treatment. It's important to note that this trial is currently recruiting participants and is designed specifically for women who meet these criteria.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Stage IA (FIGO 2009) ;
• • Pathological diagnosis: endometrial adenocarcinoma G1-G2;
• • MRI or ultrasound: tumor limited to endometrium or invading less than 1/2 of myometrium；
• • 18 years old ≤ Age ≤ 45 years old;
• • With a strong desire for fertility preservation；
• • Sign the informed consent.
• Exclusion Criteria:
• • Complicated with any other malignancy；
• • Contraindications to conservative treatment；
• • Contraindications to progestin use;
• • Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.